NIH-funded research R01 grant

A treatment to prevent heart block in babies by blocking IgG recycling during pregnancy

Official title: Atrioventricular Block Elimination by Rozanolixizumab Treatment

Funded at New York University School of Medicine · NIH-11417266 · Data updated 2026-11-12

A new approach aims to protect unborn babies from heart damage by using Rozanolixizumab to lower harmful antibodies that can cross from mother to fetus.

More Atrioventricular Block research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionNew York University School of Medicine
NIH-funded
Lab location1 site (New York, United States)
Project startSeptember 15, 2025
Project endJune 30, 2030
Funding year2026
Award (this year)$717,221
NIH project number5R01AR087521-02
Project IDNIH-11417266 on NIH RePORTER

Who could benefit from this research

Could help

Pregnant individuals known to carry autoantibodies associated with cardiac-NL and at risk for fetal heart block.

Less likely to help

Pregnancies without high-risk autoantibodies or where fetal heart block risk is low may see no benefit.

What this research studies

This study focuses on pregnant people at risk for having babies with cardiac neonatal lupus due to autoantibodies. By inhibiting the FcRn receptor, the project seeks to reduce pathogenic IgG levels that reach the fetus, potentially preventing irreversible heart block. The research builds on prior findings of autoantibodies linked to heart damage and uses maternal treatment to shield fetal heart development. Participants would be monitored for safety and fetal outcomes through pregnancy and after birth.

Why it matters

Potential benefit: If successful, the approach could reduce the risk of fetal heart block and improve long-term heart health for affected children.

How similar studies have gone: Earlier STOP BLOQ studies and related work support the concept of preventing antibody-mediated fetal disease, with evidence of autoantibody involvement in cardiac-NL.

Where this research is happening

  • New York University School of Medicine
    New York, United States
    Active

Researchers

  • Principal investigator: Buyon, Jill P — New York University School of Medicine
  • Study coordinator: Buyon, Jill P

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.